Hypotension Clinical Trial
Official title:
Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study
The prophylactic use of small doses of ephedrine may be effective in obtunding of the
hypotension responses to propofol with minimal hemodynamic and ST segment changes. The
investigators aimed to evaluate the effects of small doses of ephedrine on hemodynamic
responses of propofol anesthesia for valve surgery.
There is widespread interest in the use of propofol for the induction and maintenance of
anesthesia for fast track cardiac surgery. However, its use for induction of anesthesia is
often associated with a significant rate related transient hypotension for 5-10 minutes. This
is mainly mediated with decrease in sympathetic activity with minor contribution of its
direct vascular smooth muscle relaxation and direct negative inotropic effects.
Ephedrine has demonstrated as a vasopressor drug for the treatment of hypotension in
association with spinal and general anesthesia. Prophylactic use of high doses of ephedrine
[10-30 mg] was effective in obtunding the hypotensive response to propofol with associated
marked tachycardia. However, the use of smaller doses (0.1-0.2 mg/kg) was successfully
attenuated, but not abolished, the decrease in blood pressure with transient increase in
heart rate. This vasopressor effect is mostly mediated by β-stimulation rather than
α-stimulation and also indirectly by releasing endogenous norepinephrine from sympathetic
nerves.
Because the effect of decreasing the dose of ephedrine from 0.1 to 0.07 mg/kg may be
clinically insignificant, the investigators postulated that the prophylactic use of small
dose of ephedrine may prevent propofol-induced hypotension after induction of anesthesia for
valve surgery with minimal in hemodynamic, ST segment, and troponin I changes.
The aim of the present study was to investigate the effects of pre-induction administration
of 0.07, 0.1, 0.15 mg/kg of ephedrine on heart rate (HR), mean arterial blood pressure (MAP),
central venous and pulmonary artery occlusion pressures (CVP and PAOP, respectively), cardiac
(CI), stroke volume (SVI), systemic and pulmonary vascular resistance (SVRI and PVRI,
respectively), left and right ventricular stroke work (LVSWI and RVSWI, respectively)
indices, ST segment, and cardiac troponin I (cTnI) changes in the patients anesthetized with
propofol-fentanyl for valve surgery.
One hundred fifty ASA III-IV patients aged 18-55 years scheduled for elective valve surgery
were included in this randomized double blinded placebo-controlled study at the author's
center after obtaining of approval of the local ethical committee and a written informed
consent from the participants. The sample size was determined by a prior power analysis
indicated that 27 patients in each group would be a sufficiently large sample size to be
adequate to detect a 20% changes in SVRI values, with a type-I error of 0.05 and a power of
approximately 85%. We added 10% more patients to account for patients dropping out during the
study. All operations were performed by the same surgeons. Participants were allocated
randomly to five groups (n=30 for each) to receive saline [group 1] or ephedrine 0.07, 0.1 or
0.15 mg/kg [group 2, 3, and 4, respectively]and phenylephrine 1.5 ug/kg [group 5] 1 min
before induction of anesthesia.
Patients with documented un-controlled hypertension, ischemic heart disease, left ventricular
ejection fraction less than 45%, peripheral vascular disease, thyrotoxicosis, neurological,
hepatic, and renal diseases, pregnancy, re-do or emergency surgery, allergy to the study
medications, those requiring preoperative inotropic, vasopressor or mechanical circulatory or
ventilatory support, and those who had electrocardiograph (ECG) characteristics that would
interfere with ST segment monitoring, included baseline ST segment depression, left
bundle-branch block, atrial fibrillation, left ventricular hypertrophy, digitalis effect, QRS
duration >0.12 s, as well as pacemaker-dependent rhythms, were excluded from the study.
All routine medications except angiotensin-converting enzyme inhibitors were continued until
the morning of the operation. All patients were premedicated with 0.03 mg/kg IV midazolam and
fentanyl 1 µg/kg before invasive instrumentation. All patients were monitored with pulse
oximetry, non invasive blood pressure and five leads electrocardiography (leads II and V5)
(Life Scope Monitor, BSM-4113, Nihon Kohden Corp, Japan). Continuous ST segment trends were
electronically measured at the J-point + 60 ms to exclude the T wave during the episodes of
tachycardia. The tabulated and graphic ST segment data were reviewed by two investigators who
are not involved in the study and are blinded to the patient's group for significant ischemic
responses. The later were defined a reversible ST segment changes from baseline of either ≥ 1
mV ST-segment depression or ≥2 mV ST-segment elevation lasting for at least 1 minute. A
radial artery catheter and a flow-directed balloon-tipped pulmonary artery catheter were
placed under local anesthesia before induction. The final position of the pulmonary artery
catheter tip was confirmed with portable chest x- ray film and pulmonary artery diastolic
pressure > PAOP. CI was measured by thermodilution using ice cold injectate. Five
measurements were performed, the lowest and highest readings were discarded, and the mean of
the readings was recorded. Intravenous infusion of 5-7mL/Kg of 6% Hydroxyethyl Starch 130/0.4
(Voluven, Fresenius Kabi, Bad Hombourg, Germany) was given before induction of general
anesthesia when the baseline PAOP was less than 10 mm Hg. End-tidal carbon dioxide monitoring
and placement of a nasogastric tube, and rectal and nasopharyngeal temperature probes were
done after induction of anesthesia.
Subjects were allocated randomly to four groups by drawing sequentially numbered sealed
opaque envelopes containing a computer-generated randomization code. The subjects received
intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
[group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or
ephedrine 1.5 mg/mL [group 4 (n=30)], or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study
solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and
the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local
pharmacy department before induction of anesthesia. The anesthesia providers were blinded to
the study solution and were not involved in the study. All staff in the operating room were
unaware of the randomization code.
Anesthesia was induced with fentanyl 5 µg/kg, propofol 2-2.5 mg/kg, and cisatracurium 0.2
mg/kg was given for muscle relaxation. After endotracheal intubation, the lungs were
ventilated with a mixture of oxygen in air to maintain an arterial carbon dioxide tension at
4.5-6 kPa. Anesthesia was maintained with continuous infusions of propofol 4-6 mg/kg/ h,
fentanyl 0.025 µg/kg/min, and cisatracurium 1-3 µg/Kg/ min to maintain suppression of the
second twitch using a train-of-four stimulation. All patients received a slow injection of
tranexamic acid 50 mg/kg before initiation of CPB. Target MAP and HR were within 20% from the
mean baseline values. Hypotension (MAP ≤ 60 mm Hg ≥ 2-3 minutes) was treated with intravenous
fluids; reduction of the infusion rate of propofol by 50%, or bolus doses of ephedrine 5 mg.
Hypertension (MAP ≥ 20% from the mean baseline for ≥ 2-3 minutes) was treated with increasing
of the infusion rate of propofol by 50%, or bolus doses of labetalol 20 mg, or nitroglycerin
0.05 mg. Tachycardia ≥20% from the baseline values for ≥1 minute was treated with the
modulation of propofol infusion rate or boluses of esmolol 20 mg. Bradycardia (HR ≤ 40/min)
was treated with atropine 0.5 mg.
The cardiopulmonary bypass (CPB) lines, oxygenator, and venous reservoir were primed. Heparin
sodium 300 IU/kg was given after pericardiotomy to achieve celite-activated clotting time
became higher than 480 s. Standard CPB technique was established with the ascending aorta
cannula and the bicaval venous cannulae. During CPB, the non-pulsatile pump flow rate was 2.4
L min/ m2 using a twin roller pump and a hollow fiber membrane oxygenator, perfusion pressure
was 50-80 mmHg, arterial carbon dioxide tension was 35-40 mmHg, unadjusted for temperature
(α-stat), arterial oxygen tension was 150-250 mmHg, and moderate systemic hypothermia
(nasopharyngeal temperature 33-34°C) was maintained. Myocardial viability was preserved with
topical hypothermia and cold blood antegrade cardioplegia administered intermittently into
the aortic root.
Before separation from CPB, all patients were rewarmed (nasopharyngeal temperature 37°C,
bladder temperature 36°C) and epinephrine and nitroglycerine infusions were used to as needed
after CPB. Heparin was neutralized after discontinuation of CPB with protamine sulfate.
After surgery propofol 1-2 mg/kg/ h was used for sedation in the ICU and morphine 0.05 µg/kg
was used as needed for analgesia. Propofol infusion was discontinued and ventilator weaning
was started once patients were awake and cooperative, hemodynamically stable without high
doses of inotropic support, no severe arrhythmias, body core temperature >35.5°C, bleeding
<100 mL/h, urine output> 0.5 mL/kg/h, and arterial oxygen tension >100 mm Hg with oxygen
concentration <0.5.
Primary outcome variables include the changes in hemodynamic variables namely; HR, MAP, CI,
SVRI, LVSWI, and ST segment changes. Secondary outcome variables were CVP, PAOP, RVSWI, and
troponin I changes, and the need for vasoactive drugs. Anesthesia providers were not involved
in the assessment of the patients. Other anesthesiologists who were blinded to the study
group and were not in the operative room performed the assessment.
HR, MAP, CI, SVI, CVP, PAOP, SVRI, PVRI, LVSWI, and RVSWI changes were recorded before
(baseline), and 5 min after induction, 5, 10, 15, and 30 min after endotracheal intubation;
and 15 min after sternotomy. The changes in hemodynamic data were calculated as percentages
of the baseline measurements. The numbers and total time of intra-operative ischemic episodes
were recorded in each group. Venous blood samples were drawn before, 3, 12, 24, and 48 hours
after CPB to measure cardiac troponin I. Blood samples were centrifuged at 3,000 rpm for 10
min and serum samples stored at-20°C. Two specific monoclonal antibodies were used to avoid
the cross-reactivity with human skeletal muscle for the measurement of cTnI. The upper
reference limits for cTnI in a control population was 0.6 µg/L. The number of patients who
received rescue doses of labetalol, ephedrine, atropine and esmolol, times from induction to
intubation (I-T) and to skin incision (I-S) and all major complications (hypoxemia
(SaO2<90%), arrhythmias, respiratory failure, and cardiovascular events) were recorded in
each group.
Data were tested for normality using the Kolmogorov-Smirnov test. Repeated-measures analysis
of variance was used for analysis of serial changes in the hemodynamic and cTnI data at
different times after administration of study solution. Fisher exact test was used for
categorical data. Repeated measure analysis of variance (ANOVA) was used for continuous
parametric variables and the differences were then corrected by post-hoc Bonferoni test. The
Kruskal-Wallis one-way ANOVA was performed for intergroup comparisons for the non-parametric
values and post hoc pairwise comparisons was done using the Wilcoxon rank sum t test.
Univariate analyses of the preoperative risk factor, namely EuroSCORE for the frequency of
significant hypotension and ST segment changes after propofol anesthesia were performed.
Univariate predictors were examined in a stepwise manner into a multivariate logistic
regression model, with entry and retention set at a significance level of p < 0.05 to assess
the independent impact of this risk factor on the outcome. Data were expressed as mean (SD),
number (%), or median [range]. A value of p < 0.05 was considered to represent statistical
significance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Active, not recruiting |
NCT02016599 -
Effects of Transitional Circulation in ELBW Infants
|
||
Recruiting |
NCT05836610 -
Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates
|
Phase 4 | |
Suspended |
NCT02315937 -
Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'
|
N/A | |
Completed |
NCT02907931 -
Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status
|
N/A | |
Completed |
NCT03215797 -
Phenylephrine or Norepinephrine for a Better Hemodynamic Stability
|
Phase 3 | |
Recruiting |
NCT02532270 -
Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring
|
N/A | |
Completed |
NCT02437799 -
Dicrotic Notch and Hypotension at Caesarean Under Spinal Anaesthesia
|
N/A | |
Completed |
NCT02802683 -
Hemodynamic Impact of Hyperbaric Versus Isobaric for Spinal Anesthesia During Cesarean Delivery
|
Phase 4 | |
Completed |
NCT02146898 -
The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery
|
N/A | |
Completed |
NCT01930227 -
Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hypotension After Spinal Anesthesia in Parturients
|
N/A | |
Not yet recruiting |
NCT01941472 -
Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness
|
N/A | |
Recruiting |
NCT01434251 -
Treatment of Hypotension of Prematurity (TOHOP)
|
N/A | |
Withdrawn |
NCT01183741 -
Accuracy of Non-Invasive Blood Pressure Measurement in Adults
|
Phase 3 | |
Completed |
NCT01592669 -
Passive Leg Raising Attenuates and Delays Tourniquet Deflation-induced Hypotension and Tachycardia
|
N/A | |
Completed |
NCT00991627 -
Different Approaches to Maternal Hypotension During Cesarean Section
|
Phase 4 | |
Withdrawn |
NCT00750516 -
Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet
|
||
Completed |
NCT00115726 -
Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure
|
Phase 4 | |
Recruiting |
NCT05513066 -
Management Arterial Hypotension During Planned Caesarean Section, Intravenous Ephedrine/Phenylephrine Mixture Versus Intravenous Baby Noradrenaline
|
||
Completed |
NCT04089644 -
Manual vs Closed-loop Control of Mean Arterial Pressure
|
N/A |